Literature DB >> 16414975

Swedish registers to examine drug safety and clinical issues in RA.

J Askling1, C M Fored, P Geborek, L T H Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad, L Klareskog.   

Abstract

Data from several different monitoring systems are examined. The potential for registers based on data obtained from clinical practice, and linkage of such data to national health and population registers, is discussed. The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments.

Mesh：

Substances：

Year:  2006        PMID： 16414975      PMCID： PMC1798175          DOI： 10.1136/ard.2005.045872

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  30 in total

1.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.

Authors:  T Brewer; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

2.  COX-2 inhibitors--lessons in drug safety.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

3.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

4.  The rationale for a post-marketing surveillance.

Authors:  B Westerholm
Journal:  Hum Reprod       Date:  1987-01       Impact factor: 6.918

5.  Country profile: Sweden.

Authors:  J Calltorp; H O Adami; H Aström; L Fryklund; S Rossner; Y Trolle; J Giesecke
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

6.  The person-number systems of Sweden, Norway, Denmark, and Israel.

Authors:  A S Lunde; S Lundeborg; G S Lettenstrom; L Thygesen; J Huebner
Journal:  Vital Health Stat 2       Date:  1980

7.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

Review 8.  Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?

Authors:  T Pincus; T Sokka
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank.

Authors:  J F Fries; D J McShane
Journal:  West J Med       Date:  1986-12

10.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

Authors:  A Kastbom; G Strandberg; A Lindroos; T Skogh
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103
View more
  44 in total

1.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

Review 2.  Epidemiology research in rheumatology-progress and pitfalls.

Authors:  Deborah P M Symmons
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

Review 3.  Biologics registers in RA: methodological aspects, current role and future applications.

Authors:  Elena Nikiphorou; Maya H Buch; Kimme L Hyrich
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

4.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Authors:  Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink
Journal:  Semin Arthritis Rheum       Date:  2010-08       Impact factor: 5.532

Review 5.  Databases and registers: useful tools for research, no studies.

Authors:  Rafael J Curbelo; Estíbaliz Loza; Maria Jesús García de Yébenes; Loreto Carmona
Journal:  Rheumatol Int       Date:  2014-02-08       Impact factor: 2.631

6.  Designing a decision support system for existing clinical organizational structures: considerations from a rheumatology clinic.

Authors:  Orjan Dahlström; Ingrid Thyberg; Ursula Hass; Thomas Skogh; Toomas Timpka
Journal:  J Med Syst       Date:  2006-10       Impact factor: 4.460

7.  Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.

Authors:  Teresa A Simon; Johan Askling; Diane Lacaille; Jarrod Franklin; Frederick Wolfe; Allison Covucci; Samy Suissa; Marc C Hochberg
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

8.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

9.  Concomitant use of two or more antipsychotic drugs is common in Sweden.

Authors:  Annica Bergendal; Helena Schiöler; Björn Wettermark; Karin Sparring Björkstén
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

10.  Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.

Authors:  T A Simon; A L Smitten; J Franklin; J Askling; D Lacaille; F Wolfe; M C Hochberg; K Qi; S Suissa
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.